Semaglutide, most widely known as Ozempic and Wegovy, is a GLP-1 agonist, that mimics the peptide hormone GLP-1
According to preliminary research, SGLT2 inhibitors, GLP-1 and dual gastric inhibitory polypeptide/GLP-1 receptor agonists are promising candidates because they do show beneficial effects on apnea-hypopnia index and weight
The article says the .25 mg level is intentionally low, designed to let the body adapt and to let a provider assess tolerability, so weight loss at this stage should not be the primary metric
The claims with the most human support are all topical
For now, weekly, even monthly injectables, have a larger environmental footprint than 90 to 100 tablets in a vial, Lake noted
Gaignard, P